Chaban Ryan, Ileka Ikechukwu, Kinoshita Kohei, McGrath Gannon, Habibabady Zahra, Ma Madelyn, Diaz Victoria, Maenaka Akihiro, Rosales Ivy, Lederman Seth, Tkachev Victor, Madsen Joren C, Pierson Richard N
Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Cardiovascular Surgery, University Hospital of Mainz, Mainz, Germany.
Transplantation. 2025 Jun 1;109(6):e287-e296. doi: 10.1097/TP.0000000000005315. Epub 2025 Jan 9.
Long-term renal allograft acceptance has been achieved in macaques using a transient mixed hematopoetic chimerism protocol, but similar regimens have proven unsuccessful in heart allograft recipients unless a kidney transplant was performed simultaneously. Here, we test whether a modified protocol based on targeting CD154, CD2, and CD28 is sufficient to prolong heart allograft acceptance or promote the expansion of regulatory T cells.
Eight macaques underwent heterotopic allo-heart transplantation from major histocompatibility complex-mismatched donors. Induction treatment for donor bone marrow transplantation (BMT) was administered after a 4-mo delay period under TNX-1500 monotherapy. The BMT induction regimen comprised 1 (group 1, G1; n = 3) or 2 (group 2, G2; n = 5) doses of total body irradiation, thymic irradiation, and antithymocyte globulin, followed by 2 (G1) or 5 (G2) weekly doses of αCD2 and 5 weekly treatments with αCD28 and TNX-1500.
During the delay period, 1 G1 graft was rejected and 2 (1 in each group) exhibited moderate rejection on protocol biopsy before BMT. Lymphocyte chimerism was seen in 3 of 5 G2 animals and in 1 of 2 G1 recipients. One G1 graft was rejected despite chimerism, whereas the other recipient succumbed to anti-cytomegalovirus treatment. Two G2 monkeys succumbed due to infection (cytomegalovirus, bacteremia) post-BMT and 3 due to posttransplantation lymphoproliferative disease.
Intensive costimulation pathway blockade with αCD2, αCD154, and αCD28 promotes lymphocyte chimerism at the cost of high incidence of posttransplantation lymphoproliferative disease and opportunistic infections, preventing assessment of the effectiveness of the regimen to promote alloimmune tolerance.
在猕猴中,通过短暂混合造血嵌合方案已实现长期肾移植接受,但类似方案在心脏移植受者中被证明是不成功的,除非同时进行肾移植。在此,我们测试基于靶向CD154、CD2和CD28的改良方案是否足以延长心脏移植接受时间或促进调节性T细胞的扩增。
八只猕猴接受了来自主要组织相容性复合体不匹配供体的异位同种异体心脏移植。在TNX - 1500单药治疗4个月的延迟期后,进行供体骨髓移植(BMT)的诱导治疗。BMT诱导方案包括1次(第1组,G1;n = 3)或2次(第2组,G2;n = 5)全身照射、胸腺照射和抗胸腺细胞球蛋白,随后每周2次(G1)或5次(G2)给予αCD2,以及每周5次给予αCD28和TNX - 1500治疗。
在延迟期,1例G1移植被排斥,2例(每组1例)在BMT前的方案活检中表现为中度排斥。5例G2动物中有3例和2例G1受者中有1例出现淋巴细胞嵌合。1例G1移植尽管出现嵌合仍被排斥,而另1例受者死于抗巨细胞病毒治疗。2例G2猕猴在BMT后因感染(巨细胞病毒、菌血症)死亡,3例因移植后淋巴细胞增生性疾病死亡。
用αCD2、αCD154和αCD28进行强化共刺激途径阻断可促进淋巴细胞嵌合,但代价是移植后淋巴细胞增生性疾病和机会性感染的高发生率,从而妨碍了对该方案促进同种免疫耐受有效性的评估。